Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Nvcr save search
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 1.25%
H: 4.12%
C: -2.06%
trial glioblastoma
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
Published: 2023-08-28 (Crawled : 14:30) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -33.69%
H: 6.18%
C: -5.75%
gog-3029 update cancer tumor trial therapy
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -0.75%
H: 2.79%
C: 1.59%
favorable cancer pancreatic tumor trial therapy
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 12:00) - globenewswire.com
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: -2.43%
H: 0.67%
C: -2.98%
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 15:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 0.26%
H: 7.67%
C: 4.81%
lung presentation cancer cell meeting trial results
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 15:00) - globenewswire.com
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: 2.65%
H: 1.91%
C: -2.78%
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 0.26%
H: 7.67%
C: 4.81%
lung presentation cancer cell meeting trial results
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
Published: 2022-03-24 (Crawled : 20:00) - novocure.com
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 0.41%
H: 0.27%
C: -2.87%
ef-14 trial
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Published: 2021-11-22 (Crawled : 12:30) - novocure.com
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -4.3%
H: 0.0%
C: 0.0%
lung cancer cancer phase 3 trial enroll
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 3.0%
H: 0.39%
C: -3.17%
phase 2 positive results trial topline glioblastoma
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -4.1%
H: 0.0%
C: -4.24%
cancer phase 3 ovarian cancer trial enroll
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
Published: 2021-09-14 (Crawled : 11:00) - novocure.com
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 1.68%
H: 0.14%
C: -4.27%
treatment collaboration cancer trial pancreatic pancreas
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Published: 2021-07-01 (Crawled : 12:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -6.82%
H: 0.38%
C: -8.21%
phase 2 results cancer liver trial
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
Published: 2021-05-25 (Crawled : 12:00) - novocure.com
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -0.07%
H: 2.41%
C: 1.52%
therapy collaboration trial glioblastoma
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Published: 2021-05-24 (Crawled : 14:00) - globenewswire.com
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: -1.44%
H: 6.49%
C: 0.17%
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 0.54%
H: 3.92%
C: 1.88%
lung cancer china cancer phase 3 trial train brain metastases
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-05-18 (Crawled : 12:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 2.67%
H: 6.29%
C: 0.34%
fda lung cancer fda approval cancer phase 3 trial approval
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2021-04-22 (Crawled : 13:00) - novocure.com
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: -0.08%
H: 2.65%
C: -0.61%
fda lung cancer ide approval cancer trial approval fda ide
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial dmc recommendations decades
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.